Article PDF first page preview

First page of The Quantitively Link between Baseline Chronic Kidney Disease and Functional Decline after Minimal Invasive Partial Nephrectomy: a multicenter study

ABSTRACT Background: Baseline renal function plays a crucial role in influencing postoperative functional decline following minimal invasive partial nephrectomy (PN), yet its impact remains inadequately understood. This study aims to elucidate the relationship between baseline renal function and postoperative decline in renal function. Materials and Methods: A retrospective study was conducted on patients undergoing PN for renal tumor from 2014 to 2021 in prospectively maintained cohorts. Patients were divided into CKD (eGFR <60 mL/min/1.73 m²) and normal (eGFR ≥60 mL/min/1.73 m²) renal function groups. Restricted cubic spline (RCS) and multivariate Cox proportional hazard regressions were used to explore the relationship between baseline and postoperative renal function decline. Results: 546 patients were included for analysis. The average eGFR percent decline was found to be -8.0% (-12.1%, -4.3%), with an eGFR absolute decline of -8.2 (-16.5, -3.0) mL/min/1.73 m². Patients with severe compromised baseline function experienced higher postoperative complications and CKD-upstage compared to those with normal function (34.5% vs. 16.1%; -23.1% vs. 12.2%). Patients with CKD 3a stage were revealed to experiencing lowest functional decline even after adjusting with other well-known covariates. RCS plotted the risk of reaching >25% decline as a "U"-shaped pattern among patients with different baseline renal function. Conclusion: Patients with severe compromised baseline renal function have higher risk of perioperative complications and functional decline. The exact relationship between baseline renal function and postoperative functional decline is non-linear.

Journal Section:
Research Article
This content is only available via PDF.
S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2025
You do not currently have access to this content.